- Peptide CNLSRATKPSSRWQK, corresponding to amino acid residues 122 - 136 of rat GPR160 (Accession Q66H29). Intracellular, 2nd loop.
1 µg peptide per 1 µg antibody
GPR160 Blocking Peptide (#BLP-GR090)
- Western blot analysis of rat brain membranes (lanes 1 and 4), mouse brain membranes (lanes 2 and 5) and rat dorsal root ganglion lysate (lanes 3 and 6):1-3. Anti-GPR160 Antibody (#AGR-090), (1:200).
4-6. Anti-GPR160 Antibody, preincubated with GPR160 Blocking Peptide (BLP-GR090).
- Expression of GPR160 in mouse hippocampus.Immunohistochemical staining of perfusion-fixed frozen mouse brain sections using Anti-GPR160 Antibody (#AGR-090), (1:300), followed by goat anti-rabbit-AlexaFluor-488. A. GPR160 immunoreactivity (green) appears in the CA3 hippocampal region. B. Pre-incubation of the antibody with GPR160 Blocking Peptide (BLP-GR090), suppressed staining. Cell nuclei are stained with DAPI (blue). P = pyramidal layer.
G-protein coupled receptor 160, GP160 or GPR160, is an orphan class A GPCR that plays a role in pain signaling.1,3
GPR160 is composed of 338 amino acids, encoded by 7 exons located at 3q26.2-q27, demonstrates a significant degree of conservation across various species, and is expressed in neurons, astrocytes, and microglia within the central nervous system (CNS) and spinal cord.3
Cocaine- and amphetamine-regulated transcript peptide (CARTp) exhibits various pharmacological actions in the CNS, peripheral nervous system, and several endocrine organs. It plays a role in reward and addiction, anxiety and depression, and food intake and body weight maintenance. It has been found that the interaction between CARTp and GPR160 is essential for the circadian regulation of appetite and thirst as well as the transmission of pain signals induced by nerve injury. GPR160 has been shown to confer CARTp-induced cFOS and ERK phosphorylation and activation of CREB independently of cAMP signaling. ERK can function as an upstream regulator of CREB phosphorylation during the development of neuropathic pain. As a putative ligand for GPR160, endogenous CARTp inhibition has been shown to mitigate neuropathic pain.1,2
GPR160 has also been shown to play a role in the pathogenesis of prostate cancer. Transcription profiles demonstrate a marked increase of GPR160 mRNA in all stages of prostate cancer samples and cancer cell lines, except prostate hyperplasia tissues, with levels comparable to those in stage II-IV cancer patients. GPR160 knockdown increased caspase 1 and IL-6 expression and induced cell cycle arrest and apoptosis. The involvement of GPR160 in prostate carcinogenicity has therapeutic implications for exploring diagnostics and pharmaceutical interventions.3
Species reactivity key:
Anti-GPR160 Antibody (#AGR-090) is a highly specific antibody directed against an epitope of the rat protein. The antibody can be used in western blot and immunohistochemistry applications. It has been designed to recognize GPR160 from rat and mouse samples. The antibody will not recognize human GPR160.